![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Böhler Steffen Pittrow David Bramlage Peter Kirch Wilhelm
Publisher: Informa Healthcare
ISSN: 1474-0338
Source: Expert Opinion on Drug Safety, Vol.4, Iss.1, 2005-01, pp. : 7-18
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Angiotensin receptor blockers and drug–drug interactions
Expert Opinion on Drug Safety, Vol. 4, Iss. 1, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Vascular benefits of angiotensin receptor blockers
Expert Opinion on Investigational Drugs, Vol. 16, Iss. 7, 2007-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Angiotensin Receptor Blockers and the Risk of Malignancy: A Note of Caution
Drug Safety, Vol. 33, Iss. 9, 2010-09 ,pp. :